Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
 announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Nov. 16, 2016 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed in Michigan on behalf of certain purchasers of shares of Diplomat Pharmacy Inc (NYSE:DPLO) over alleged Securities Laws Violations by Diplomat Pharmacy. The lawsuit seeks to recover damages for certain NYSE:DPLO investors.
Investors who purchased shares of Diplomat Pharmacy Inc (NYSE: DPLO) have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that Diplomat Pharmacy Inc lacked adequate internal controls over its financial reporting, that as a result Diplomat Pharmacy Inc could not adequately calculate DIR fees, that the Company’s hepatitis C segment was not performing as previously disclosed to investors, that and therefore, Diplomat Pharmacy Inc had overstated its full-year 2016 guidance, and that, as a result of the foregoing, defendants’ statements about Diplomat Pharmacy Inc’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
On November 2, 2016, Diplomat Pharmacy Inc reported third quarter 2016 results. Diplomat Pharmacy Inc also lowered full year 2016 guidance, with the CEO and Chairman commenting, “We are disappointed with our third quarter results, which were significantly impacted by the softness in the hepatitis C business nationwide, as well as by DIR fees. The methodology and transparency around how PBMs are applying these DIR fees changed materially in 2016, and while we cannot reverse the impact they had on this quarter, we are working with our partners in the specialty pharmacy industry and with legislators to achieve an amicable solution to this problem.”
Shares of Diplomat Pharmacy Inc (NYSE: DPLO) declined to as low as $12.47 per share on November 4, 2016.
Those who purchased Diplomat Pharmacy Inc (NYSE: DPLO) shares should contact the Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108
